1
|
Wong PF, Isakova-Sivak I, Stepanova E, Krutikova E, Bazhenova E, Rekstin A, Rudenko L. Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus. Vaccines (Basel) 2024; 12:95. [PMID: 38250908 PMCID: PMC10821225 DOI: 10.3390/vaccines12010095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 12/30/2023] [Accepted: 01/16/2024] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND Influenza viruses continue to cause a significant social and economic burden globally. Vaccination is recognized as the most effective measure to control influenza. Live attenuated influenza vaccines (LAIVs) are an effective means of preventing influenza, especially among children. A reverse genetics (RG) system is required to rapidly update the antigenic composition of vaccines, as well as to design LAIVs with a broader spectrum of protection. Such a system has been developed for the Russian LAIVs only for type A strains, but not for influenza B viruses (IBV). METHODS All genes of the B/USSR/60/69 master donor virus (B60) were cloned into RG plasmids, and the engineered B60, as well as a panel of IBV LAIV reassortants were rescued from plasmid DNAs encoding all viral genes. The engineered viruses were evaluated in vitro and in a mouse model. RESULTS The B60 RG system was successfully developed, which made it possible to rescue LAIV reassortants with the desired antigenic composition, including hybrid strains with hemagglutinin and neuraminidase genes belonging to the viruses from different IBV lineages. The LAIV candidate carrying the HA of the B/Victoria-lineage virus and NA from the B/Yamagata-lineage virus demonstrated optimal characteristics in terms of safety, immunogenicity and cross-protection, prompting its further assessment as a broadly protective component of trivalent LAIV. CONCLUSIONS The new RG system for B60 MDV allowed the rapid generation of type B LAIV reassortants with desired genome compositions. The generation of hybrid LAIV reassortants with HA and NA genes belonging to the opposite IBV lineages is a promising approach for the development of IBV vaccines with broad cross-protection.
Collapse
Affiliation(s)
| | - Irina Isakova-Sivak
- Department of Virology, Institute of Experimental Medicine, 197022 St. Petersburg, Russia; (P.-F.W.); (E.S.); (E.K.); (E.B.); (A.R.); (L.R.)
| | | | | | | | | | | |
Collapse
|
2
|
Coleman BL, Gutmanis I, McGovern I, Haag M. Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2023; 11:1607. [PMID: 37897009 PMCID: PMC10610589 DOI: 10.3390/vaccines11101607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 10/05/2023] [Accepted: 10/13/2023] [Indexed: 10/29/2023] Open
Abstract
Cell-based seasonal influenza vaccine viruses may more closely match recommended vaccine strains than egg-based options. We sought to evaluate the effectiveness of seasonal cell-based quadrivalent influenza vaccine (QIVc), as reported in the published literature. A systematic literature review was conducted (PROSPERO CRD42020160851) to identify publications reporting on the effectiveness of QIVc in persons aged ≥6 months relative to no vaccination or to standard-dose, egg-based quadrivalent or trivalent influenza vaccines (QIVe/TIVe). Publications from between 1 January 2016 and 25 February 2022 were considered. The review identified 18 relevant publications spanning three influenza seasons from the 2017-2020 period, with an overall pooled relative vaccine effectiveness (rVE) of 8.4% (95% CI, 6.5-10.2%) for QIVc vs. QIVe/TIVe. Among persons aged 4-64 years, the pooled rVE was 16.2% (95% CI, 7.6-24.8%) for 2017-2018, 6.1% (4.9-7.3%) for 2018-2019, and 10.1% (6.3-14.0%) for 2019-2020. For adults aged ≥65 years, the pooled rVE was 9.9% (95% CI, 6.9-12.9%) in the egg-adapted 2017-2018 season, whereas there was no significant difference in 2018-2019. For persons aged 4-64 years, QIVc was consistently more effective than QIVe/TIVe over the three influenza seasons. For persons aged ≥65 years, protection with QIVc was greater than QIVe or TIVe during the 2017-2018 season and comparable in 2018-2019.
Collapse
Affiliation(s)
- Brenda L. Coleman
- Sinai Health, Toronto, ON M5G 2A2, Canada;
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
- Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada
| | - Iris Gutmanis
- Sinai Health, Toronto, ON M5G 2A2, Canada;
- Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada
| | | | - Mendel Haag
- CSL Seqirus, 1105 BJ Amsterdam, The Netherlands
| |
Collapse
|
3
|
Xiao T, Wei M, Guo X, Zhang Y, Wang Z, Xia X, Qi X, Wang L, Li X, Leng SX. Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor. Immun Ageing 2023; 20:37. [PMID: 37501123 PMCID: PMC10373264 DOI: 10.1186/s12979-023-00364-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 07/15/2023] [Indexed: 07/29/2023]
Abstract
BACKGROUND Older adults are more vulnerable to seasonal influenza than younger adults. The immune responses of older persons to the influenza vaccine are usually poorer than those of young individuals, which is hypothesized due to immunosenescence. We conducted a study to evaluate the immunogenicity and safety of a quadrivalent inactivated influenza vaccine (IIV4) in a total of 167 young (< 65 years, n = 79) and older (≥ 65 years, n = 88) adults from October 2021 to March 2022 in Tianjin, China. A single dose was administered to all participants. Blood samples were collected and strain-specific hemagglutination inhibition (HAI) antibody titers were measured before and 21 to 28 days after vaccination. Safety information was also collected for 28 days and 6 months after vaccination. Differences in immunogenicity and safety were compared between young and old age groups, and multivariate logistic regression was used to estimate the effect of age and other factors on HAI antibody responses. RESULTS Overall, geometric mean titers (GMTs) against all four vaccine strains in older adults were lower than those in the young, whereas the seroconversion rates (SCRs) were similar. Multivariate logistic regression analysis showed that age, influenza vaccination history, and pre-vaccination HAI titers were independent factors affecting SCRs and seroprotection rates (SCRs). Older age had significant negative impact on SCRs against H1N1 (OR, 0.971; 95% CI: 0.944-0.999; P = 0.042) and B/Victoria (OR, 0.964; 95% CI: 0.937-0.992; P = 0.011). In addition, there was a significant negative correlation between chronological age (years) and post-vaccination HAI titers against H1N1 (rho = -0.2298, P < 0.0001), B/Victoria (rho = -0.2235, P = 0.0037), and B/Yamagata (rho = -0.3689, P < 0.0001). All adverse events were mild (grade 1 or grade 2) that occurred within 28 days after vaccination, and no serious adverse event was observed. CONCLUSIONS IIV4 is immunogenic and well-tolerated in young and older adults living in Tianjin, China. Our findings also indicate that age is an independent factor associated with poorer humoral immune responses to IIV4.
Collapse
Affiliation(s)
- Tongling Xiao
- Department of Neurology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin, 300211, China
| | - Miaomiao Wei
- Department of Neurology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin, 300211, China
| | - Xiaokun Guo
- Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Yu Zhang
- Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Zhongyan Wang
- Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Xiaoshuang Xia
- Department of Neurology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin, 300211, China
| | - Xuemei Qi
- Department of Neurology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin, 300211, China
| | - Lin Wang
- Department of Geriatrics, The Second Hospital of Tianjin Medical University, Tianjin, China
| | - Xin Li
- Department of Neurology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin, 300211, China.
| | - Sean X Leng
- Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- School of Medicine and Bloomberg School of Public Health, Division of Geriatric, Johns Hopkins Center On Aging and Immune Remodeling, Johns Hopkins University, JHAAC Room 1A.38A, 5501 Hopkins Bayview Circle, Baltimore, MD, 21224, USA.
| |
Collapse
|
4
|
Ye B, Shu L, Pang Y, Guo Y, Guo Y, Zong K, Chen C, Zheng X, Zhang J, Liu M, Yuan X, Zhao Y, Zhang D, Wang D, Bao C, Zhang J, Chen L, Gao GF, Liu WJ. Repeated influenza vaccination induces similar immune protection as first-time vaccination but with differing immune responses. Influenza Other Respir Viruses 2022; 17:e13060. [PMID: 36271687 PMCID: PMC9835420 DOI: 10.1111/irv.13060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 09/21/2022] [Accepted: 09/24/2022] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND Recent seasonal epidemics of influenza have been caused by human influenza A viruses of the H1N1 and H3N2 subtypes and influenza B viruses. Annual vaccination is recommended to prevent infection; however, how annual influenza vaccination influences vaccine effectiveness is largely unknown. METHODS To investigate the impact of repeated vaccination on immune and protective effect, we performed a prospective seroepidemiologic study. Participants with or without prior vaccination (2018-2019) were enrolled during the 2019-2020 influenza season. Inactivated quadrivalent influenza vaccine (IIV4) was administered through the intramuscular route, and venous blood samples were collected regularly to test hemagglutination inhibition (HAI) titers. RESULTS The geometric mean titers and proportion with titers ≥40 against the influenza vaccine components peaked at 30 days post-vaccination. At Day 30, the geometric mean titer and proportion with titers ≥40 in participants who had been previously vaccinated were higher for H3N2 but similar for both B lineages (Victoria and Yamagata) as compared with participants vaccinated for the first time. As for H1N1, the geometric mean titer was lower in repeated vaccinated participants, but the proportion with titers ≥40 was consistent in both groups. CONCLUSIONS Repeated vaccination provides similar or enhanced protection as compared with single vaccination in first-time vaccinees.
Collapse
Affiliation(s)
- Beiwei Ye
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Liumei Shu
- Department of Health CareBeijing Daxing District HospitalBeijingChina
| | - Yuanyuan Pang
- Suzhou Municipal Center for Disease Control and PreventionSuzhouJiangsuChina
| | - Yaxin Guo
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Yuanyuan Guo
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina,Department of Epidemiology, School of Public Health, Cheeloo College of MedicineShandong UniversityJinanShandongChina
| | - Kexin Zong
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Cong Chen
- Changzhou Center for Disease Control and PreventionChangzhouJiangsuChina
| | - Xianzhi Zheng
- Changzhou Center for Disease Control and PreventionChangzhouJiangsuChina
| | - Jie Zhang
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Maoshun Liu
- School of Laboratory Medicine and Life SciencesWenzhou Medical UniversityWenzhouZhejiangChina
| | - Xiaoju Yuan
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Yingze Zhao
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Danni Zhang
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Dayan Wang
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina
| | - Changjun Bao
- Jiangsu Provincial Center for Disease Control and PreventionNanjingJiangsuChina
| | - Jun Zhang
- Suzhou Municipal Center for Disease Control and PreventionSuzhouJiangsuChina
| | - Liling Chen
- Suzhou Municipal Center for Disease Control and PreventionSuzhouJiangsuChina
| | - George F. Gao
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina,School of Laboratory Medicine and Life SciencesWenzhou Medical UniversityWenzhouZhejiangChina,CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of MicrobiologyChinese Academy of Sciences (CAS)BeijingChina,Research Unit of Adaptive Evolution and Control of Emerging VirusesChinese Academy of Medical SciencesBeijingChina
| | - William J. Liu
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and PreventionChinese Center for Disease Control and Prevention (China CDC)BeijingChina,School of Laboratory Medicine and Life SciencesWenzhou Medical UniversityWenzhouZhejiangChina,Research Unit of Adaptive Evolution and Control of Emerging VirusesChinese Academy of Medical SciencesBeijingChina
| |
Collapse
|